| The pancreatic cancer is a familiar malignant tumor in digestive system characterized by high malignant degree, rapid progress and poor prognosis. Its incidence rate showed an increasing tendency within the scope of world in recent years. Nevertheless, the anatomical character and biologic behavior of easy metastasis retard the therapy of pancreatic cancer. Recently, the understanding of molecular processes associated with the development and progression of the disease is helping tailor more effective treatment strategies. The tumor molecular target therapy has emerged as an efficient alternative characterized high specific, significant effects and no-imperiling normal tissues. Monoclonal antibody therapy are offering hope for their potential role in helping translate the improved activity of combing chemotherapy into improved survival.HEC-252 is a novel tumor gene cloned and identified from cDNA library of Human Umbilical Vein Endothelial Cell (HUVEC). Bio-informatic analysis shows that HEC-252 has no homology with other human genes. Whether HEC-252 gene is correlated with pancreatic cancer remains unknown. This work mainly focused on the study of HEC-252 gene from protein level to investigate the correlation between HEC-252 and pancreatic cancer, and thus provided useful data to support the hypothesis and feasibility of HEC-252 could be a new target of tumor target therapy.In this study, a peptide of HEC-252 extracellular region was synthesized and linked with keyhole limpet hemocyanin to prepare polyclonal antibody. Live cell immunofiuorescence and confocal microscopy were performed to determine the subcellular localization of HEC-252. The expression profiles of HEC-252 in normal human tissues, multiple tumor cells and tissues were determined by immunohistochemical analysis. We put effort to study the HEC-252 expression status in pancreatic cancer and their correlation by immunocytochemical and immunohistochemical analysis. In view of the valuable results of above experiments,... |
PDF Full Text Request